A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Han, 2003, Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer, J Urol, 169, 517, 10.1016/S0022-5347(05)63946-8
D’Amico, 2002, Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era, Cancer, 95, 281, 10.1002/cncr.10657
Stephenson, 2007, Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy, J Clin Oncol, 25, 2035, 10.1200/JCO.2006.08.9607
Kuban, 2006, Comparison of biochemical failure definitions for permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 65, 1487, 10.1016/j.ijrobp.2006.03.027
Cheung, 2005, Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy, Int J Radiat Oncol Biol Phys, 61, 14, 10.1016/j.ijrobp.2004.04.064
Giannarini, 2018, Will image-guided metastasis-directed therapy change the treatment paradigm of oligorecurrent prostate cancer?, Eur Urol, 74, 131, 10.1016/j.eururo.2018.03.021
Tendulkar, 2016, Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy, J Clin Oncol, 34, 3648, 10.1200/JCO.2016.67.9647
King, 2008, Radiotherapy after prostatectomy: is the evidence for dose escalation out there?, Int J Radiat Oncol Biol Phys, 71, 346, 10.1016/j.ijrobp.2007.10.008
Umbehr, 2013, The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis, Eur Urol, 64, 106, 10.1016/j.eururo.2013.04.019
Wu, 2013, Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy, Clin Oncol, 25, 252, 10.1016/j.clon.2012.11.010
Fanti, 2016, PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data, Eur J Nucl Med Mol Imaging, 43, 55, 10.1007/s00259-015-3202-7
Whiting, 2011, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 155, 529, 10.7326/0003-4819-155-8-201110180-00009
Moher, 2015, Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) 2015 statement, Syst Rev, 4, 1, 10.1186/2046-4053-4-1
Shamseer, 2015, Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) 2015: elaboration and explanation, BMJ, 350, g7647, 10.1136/bmj.g7647
Walz, 2009, Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer, J Urol, 181, 601, 10.1016/j.juro.2008.10.033
Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591
Lamanna, 2017, Long-term results of a comparative PET/CT and PET/MRI study of 11C-acetate and 18F-fluorocholine for restaging of early recurrent prostate cancer, Clin Nucl Med, 42, e242, 10.1097/RLU.0000000000001609
Buchegger, 2014, First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy, Eur J Nucl Med Mol Imaging, 41, 68, 10.1007/s00259-013-2540-6
Hovels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022
Kitajima, 2014, Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil, J Nucl Med, 55, 223, 10.2967/jnumed.113.123018
Rinnab, 2008, [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study, Urol Int, 81, 191, 10.1159/000144059
Scattoni, 2007, Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy, Eur Urol, 52, 423, 10.1016/j.eururo.2007.03.032
Lecouvet, 2010, Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa), Eur Radiol, 20, 2973, 10.1007/s00330-010-1879-3
Cumming, 1990, Distribution of bony metastases in prostatic carcinoma, Br J Urol, 66, 411, 10.1111/j.1464-410X.1990.tb14964.x
Vadi, 2017, 18F-fluorocholine PET/CT complementing the role of dynamic contrast-enhanced MRI for providing comprehensive diagnostic workup in prostate cancer patients with suspected relapse following radical prostatectomy, Clin Nucl Med, 42, e355, 10.1097/RLU.0000000000001689
Freitag, 2017, Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI, Eur J Nucl Med Mol Imaging, 44, 776, 10.1007/s00259-016-3594-z
Pasoglou, 2014, One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach?, Prostate, 74, 469, 10.1002/pros.22764
Robertson, 2017, Combined whole body and multiparametric prostate magnetic resonance imaging as a 1-step approach to the simultaneous assessment of local recurrence and metastatic disease after radical prostatectomy, J Urol, 198, 65, 10.1016/j.juro.2017.02.071
Chondrogiannis, 2013, Role of (1)(8)F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer, Eur J Nucl Med Mol Imaging, 40, 1356, 10.1007/s00259-013-2433-8
Einspieler, 2017, Detection efficacy of hybrid (68)Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria, J Nucl Med, 58, 1081, 10.2967/jnumed.116.184457
Johnson, 2016, Predictive factors of (18)F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?, EJNMMI Res, 6, 84, 10.1186/s13550-016-0237-0
Gupta, 2017, Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning, Int J Radiat Oncol Biol Phys, 99, 701, 10.1016/j.ijrobp.2017.06.2448
Meredith, 2016, The use of (68) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer, BJU Int, 118, 49, 10.1111/bju.13616
Connolly, 1996, Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins, Urology, 47, 225, 10.1016/S0090-4295(99)80421-X
Deliveliotis, 2007, Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy, World J Urol, 25, 309, 10.1007/s00345-007-0167-6
Kotzerke, 2002, Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer, Eur J Nucl Med Mol Imaging, 29, 1380, 10.1007/s00259-002-0882-6
Leventis, 2001, Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings, Radiology, 219, 432, 10.1148/radiology.219.2.r01ma20432
Linder, 2014, Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging, Can J Urol, 21, 7283
Scattoni, 2003, Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage, Eur Urol, 44, 407, 10.1016/S0302-2838(03)00320-8
Jilg, 2014, Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography, J Urol, 192, 103, 10.1016/j.juro.2013.12.054
Osmonov, 2014, Sensitivity and specificity of PET/CT regarding the detection of lymph node metastases in prostate cancer recurrence, Springerplus, 3, 340, 10.1186/2193-1801-3-340
Passoni, 2014, Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series, Urol Oncol, 32, 10.1016/j.urolonc.2013.03.006
Rouviere, 2010, Imaging of prostate cancer local recurrences: why and how?, Eur Radiol, 20, 1254, 10.1007/s00330-009-1647-4
Rouviere, 2012, Imaging techniques for local recurrence of prostate cancer: for whom, why and how?, Diagn Interv Imaging, 93, 279, 10.1016/j.diii.2012.01.012
Kramer, 1997, Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy, Br J Radiol, 70, 995, 10.1259/bjr.70.838.9404201
Kane, 2003, Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy, Urology, 61, 607, 10.1016/S0090-4295(02)02411-1
Cimitan, 2006, [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients, Eur J Nucl Med Mol Imaging, 33, 1387, 10.1007/s00259-006-0150-2
Odewole, 2016, Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT, Eur J Nucl Med Mol Imaging, 43, 1773, 10.1007/s00259-016-3383-8
Seltzer, 1999, Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer, J Urol, 162, 1322, 10.1016/S0022-5347(05)68277-8
Albrecht, 2007, (11)C-acetate PET in the early evaluation of prostate cancer recurrence, Eur J Nucl Med Mol Imaging, 34, 185, 10.1007/s00259-006-0163-x
Counago, 2015, Role of 3T multiparametric magnetic resonance imaging without endorectal coil in the detection of local recurrent prostate cancer after radical prostatectomy: the radiation oncology point of view, Scand J Urol, 49, 360, 10.3109/21681805.2015.1004643
Liauw, 2013, Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging, Int J Radiat Oncol Biol Phys, 85, 378, 10.1016/j.ijrobp.2012.05.015
Panebianco, 2012, Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP), Eur J Radiol, 81, 700, 10.1016/j.ejrad.2011.01.095
Panebianco, 2013, Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging, Eur Radiol, 23, 1745, 10.1007/s00330-013-2768-3
Rischke, 2012, Detection of local recurrent prostate cancer after radical prostatectomy in terms of salvage radiotherapy using dynamic contrast enhanced-MRI without endorectal coil, Radiat Oncol, 7, 185, 10.1186/1748-717X-7-185
Sciarra, 2008, Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer, Eur Urol, 54, 589, 10.1016/j.eururo.2007.12.034
Vees, 2007, 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1ng/mL) after radical prostatectomy, BJU Int, 99, 1415, 10.1111/j.1464-410X.2007.06772.x
Cher, 1998, Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy, J Urol, 160, 1387, 10.1016/S0022-5347(01)62545-X
Picchio, 2012, [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy, Eur J Nucl Med Mol Imaging, 39, 13, 10.1007/s00259-011-1920-z
Su, 2017, Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse, Asian J Androl, 19, 267, 10.4103/1008-682X.192638
Schuster, 2016, PET tracers beyond FDG in prostate cancer, Semin Nucl Med, 46, 507, 10.1053/j.semnuclmed.2016.07.005
Oyama, 2003, 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse, J Nucl Med, 44, 549
Richter, 2010, Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment, Mol Imaging Biol, 12, 210, 10.1007/s11307-009-0243-y
Schoder, 2005, 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy, Clin Cancer Res, 11, 4761, 10.1158/1078-0432.CCR-05-0249
Brogsitter, 2013, 18F-choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients, Eur J Nucl Med Mol Imaging, 40, S18, 10.1007/s00259-013-2358-2
Kitajima, 2013, Choline PET/CT for imaging prostate cancer: an update, Ann Nucl Med, 27, 581, 10.1007/s12149-013-0731-7
de Jong, 2003, 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer, Eur Urol, 44, 32, 10.1016/S0302-2838(03)00207-0
Bertagna, 2011, Role of (1)(1)C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation, Jpn J Radiol, 29, 394, 10.1007/s11604-011-0570-1
Castellucci, 2009, Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy, J Nucl Med, 50, 1394, 10.2967/jnumed.108.061507
Castellucci, 2011, Is there a role for (1)(1)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5ng/ml?, Eur J Nucl Med Mol Imaging, 38, 55, 10.1007/s00259-010-1604-0
Castellucci, 2014, Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?, J Nucl Med, 55, 1424, 10.2967/jnumed.114.138313
Eiber, 2017, Prospective head-to-head comparison of (11)C-choline-PET/MR and (11)C-choline-PET/CT for restaging of biochemical recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 44, 2179, 10.1007/s00259-017-3797-y
Giovacchini, 2013, [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen, J Urol, 189, 105, 10.1016/j.juro.2012.09.001
Giovacchini, 2010, Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy, Eur J Nucl Med Mol Imaging, 37, 301, 10.1007/s00259-009-1253-3
Gomez-de la Fuente, 2018, Contribution of (11)C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1ng/ml, Rev Esp Med Nucl Imagen Mol, 37, 156
Graziani, 2016, (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series, Eur J Nucl Med Mol Imaging, 43, 1971, 10.1007/s00259-016-3428-z
Krause, 2008, The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer, Eur J Nucl Med Mol Imaging, 35, 18, 10.1007/s00259-007-0581-4
Mamede, 2013, The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5ng/mL, Clin Nucl Med, 38, e342, 10.1097/RLU.0b013e31829af913
Mitchell, 2013, Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment, J Urol, 189, 1308, 10.1016/j.juro.2012.10.069
Nanni, 2016, (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial, Eur J Nucl Med Mol Imaging, 43, 1601, 10.1007/s00259-016-3329-1
Rinnab, 2007, Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer, BJU Int, 100, 786, 10.1111/j.1464-410X.2007.07083.x
Rinnab, 2009, [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy, World J Urol, 27, 619, 10.1007/s00345-009-0371-7
Rybalov, 2013, Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer, World J Urol, 31, 319, 10.1007/s00345-012-0908-z
Souvatzoglou, 2011, Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer, Radiother Oncol, 99, 193, 10.1016/j.radonc.2011.05.005
Wieder, 2017, 11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer, Oncotarget, 8, 66516, 10.18632/oncotarget.16227
Henninger, 2012, [18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy—a preliminary study, Nucl Med Commun, 33, 889, 10.1097/MNM.0b013e328355990f
Simone, 2015, Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with (1)(8)F-fluorocholine positron emission tomography/computed tomography, World J Urol, 33, 1511, 10.1007/s00345-015-1481-z
Chiaravalloti, 2016, PET/CT with (18)F-choline after radical prostatectomy in patients with PSA </=2ng/ml. Can PSA velocity and PSA doubling time help in patient selection?, Eur J Nucl Med Mol Imaging, 43, 1418, 10.1007/s00259-015-3306-0
Cimitan, 2015, Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients, J Nucl Med, 56, 209, 10.2967/jnumed.114.141887
Detti, 2013, Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment, J Cancer Res Clin Oncol, 139, 521, 10.1007/s00432-012-1354-4
Gauvin, 2017, Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent, Can Urol Assoc J, 11, 47, 10.5489/cuaj.4068
Heinisch, 2006, Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5ng/ml?, Mol Imaging Biol, 8, 43, 10.1007/s11307-005-0023-2
Kwee, 2012, Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging, Ann Nucl Med, 26, 501, 10.1007/s12149-012-0601-8
Marzola, 2013, Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution, Clin Nucl Med, 38, e26, 10.1097/RLU.0b013e318266cc38
Morigi, 2015, Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy, J Nucl Med, 56, 1185, 10.2967/jnumed.115.160382
Pelosi, 2008, Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer, Radiol Med, 113, 895, 10.1007/s11547-008-0263-8
Rodado-Marina, 2015, Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study, BJU Int, 115, 874, 10.1111/bju.12953
Schillaci, 2012, Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy, Eur J Nucl Med Mol Imaging, 39, 589, 10.1007/s00259-011-2030-7
Almeida, 2017, Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer, Am J Nucl Med Mol Imaging, 7, 1
Dusing, 2014, Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence, Clin Nucl Med, 39, 777, 10.1097/RLU.0000000000000516
Esch, 2017, 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer, BJU Int, 120, 337, 10.1111/bju.13706
Sandblom, 2006, Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy, Urology, 67, 996, 10.1016/j.urology.2005.11.044
Bach-Gansmo, 2017, Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine ((18)F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer, J Urol, 197, 676, 10.1016/j.juro.2016.09.117
Bostwick, 1998, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases, Cancer, 82, 2256, 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
Elgamal, 1998, ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients, Prostate, 37, 261, 10.1002/(SICI)1097-0045(19981201)37:4<261::AID-PROS8>3.0.CO;2-#
Raj, 2002, Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy, Cancer, 94, 987, 10.1002/cncr.10337
Petronis, 1998, Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer, Clin Nucl Med, 23, 672, 10.1097/00003072-199810000-00005
Sodee, 1996, Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer, Clin Nucl Med, 21, 759, 10.1097/00003072-199610000-00002
Afshar-Oromieh, 2014, Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 41, 11, 10.1007/s00259-013-2525-5
Afshar-Oromieh, 2015, The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, 197, 10.1007/s00259-014-2949-6
Afshar-Oromieh, 2017, Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients, Eur J Nucl Med Mol Imaging, 44, 1258, 10.1007/s00259-017-3711-7
Calais, 2018, (68)Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0ng/ml: impact on salvage radiotherapy planning, J Nucl Med, 59, 230, 10.2967/jnumed.117.201749
Ceci, 2015, (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?, Eur J Nucl Med Mol Imaging, 42, 1284, 10.1007/s00259-015-3078-6
Dietlein, 2017, PSA-stratified performance of (18)F- and (68)Ga-PSMA PET in patients with biochemical recurrence of prostate cancer, J Nucl Med, 58, 947, 10.2967/jnumed.116.185538
Eiber, 2015, Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, 56, 668, 10.2967/jnumed.115.154153
Lengana, 2018, 68Ga-PSMA-HBED-CC PET/CT imaging in black versus white South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study, Nucl Med Commun, 39, 179, 10.1097/MNM.0000000000000791
Rauscher, 2018, Efficacy, predictive factors, and prediction nomograms for (68)Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy, Eur Urol, 73, 656, 10.1016/j.eururo.2018.01.006
Sachpekidis, 2016, (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer, Eur J Nucl Med Mol Imaging, 43, 1288, 10.1007/s00259-015-3302-4
Sanli, 2017, Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer, Ann Nucl Med, 31, 709, 10.1007/s12149-017-1207-y
Verburg, 2016, Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score, Eur J Nucl Med Mol Imaging, 43, 397, 10.1007/s00259-015-3240-1
Grubmuller, 2018, (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy—diagnostic performance and impact on therapeutic decision-making, Eur J Nucl Med Mol Imaging, 45, 235, 10.1007/s00259-017-3858-2
Hope, 2017, Impact of (68)Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer, J Nucl Med, 58, 1956, 10.2967/jnumed.117.192476
Kranzbuhler, 2018, Clinical performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy, Eur J Nucl Med Mol Imaging, 45, 20, 10.1007/s00259-017-3850-x
Derlin, 2018, PSA-stratified detection rates for [(68)Ga]THP-PSMA, a novel probe for rapid kit-based (68)Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer, Eur J Nucl Med Mol Imaging, 45, 913, 10.1007/s00259-017-3924-9
Schmuck, 2017, Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer, Eur J Nucl Med Mol Imaging, 44, 960, 10.1007/s00259-017-3669-5
Berliner, 2017, Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC, Eur J Nucl Med Mol Imaging, 44, 670, 10.1007/s00259-016-3572-5
Maurer, 2016, Diagnostic EFFICACY of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer, J Urol, 195, 1436, 10.1016/j.juro.2015.12.025
Mena, 2018, Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy, Eur J Nucl Med Mol Imaging, 45, 4, 10.1007/s00259-017-3818-x
Giesel, 2018, Detection efficacy of [(18)F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy, J Nucl Med
Giesel, 2018, Biochemical recurrence of prostate cancer: initial results with [(18)F]PSMA-1007 PET/CT, J Nucl Med, 59, 632, 10.2967/jnumed.117.196329
Rahbar, 2018, Advantage of (18)F-PSMA-1007 over (68)Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion, Eur J Nucl Med Mol Imaging, 45, 1076, 10.1007/s00259-018-3952-0
Reinfelder, 2017, First experience with SPECT/CT using a 99mTc-labeled inhibitor for prostate-specific membrane antigen in patients with biochemical recurrence of prostate cancer, Clin Nucl Med, 42, 26, 10.1097/RLU.0000000000001433
Eiber, 2011, Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI, J Magn Reson Imaging, 33, 1160, 10.1002/jmri.22542
Lecouvet, 2007, Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies, J Clin Oncol, 25, 3281, 10.1200/JCO.2006.09.2940
Meijer, 2012, High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy, Int J Radiat Oncol Biol Phys, 82, 1405, 10.1016/j.ijrobp.2011.04.054
Lecouvet, 2016, Whole-body MR imaging: musculoskeletal applications, Radiology, 279, 345, 10.1148/radiol.2016142084
Beheshti, 2012, Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients, Eur J Nucl Med Mol Imaging, 39, 910, 10.1007/s00259-011-2046-z
Afshar-Oromieh, 2018, Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer, Eur J Nucl Med Mol Imaging, 45, 2045, 10.1007/s00259-018-4079-z
Larbi, 2016, Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease, Prostate, 76, 1024, 10.1002/pros.23196
Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853
Maurer, 2015, Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer, Eur Urol, 68, 530, 10.1016/j.eururo.2015.04.034
Rauscher, 2017, Value of (111) In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up, BJU Int, 120, 40, 10.1111/bju.13713
Maurer, 2018, (99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer, Eur Urol
deSouza, 2018, Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group, Eur J Cancer, 91, 153, 10.1016/j.ejca.2017.12.012
Murphy, 2017, “Gotta catch’em all”, or do we? Pokemet approach to metastatic prostate cancer, Eur Urol, 72, 1, 10.1016/j.eururo.2017.02.036
Joice, 2017, Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology, Curr Opin Urol, 27, 533, 10.1097/MOU.0000000000000449
Eiber, 2016, (68)Ga-labeled prostate-specific membrane antigen positron emission tomography for prostate cancer imaging: the new kid on the block—early or too early to draw conclusions?, Eur Urol, 70, 938, 10.1016/j.eururo.2016.07.045